Discover the Novartis pipeline of over 100 projects in clinical development, many for medicines that could advance treatment standards for ...

18 июл. 2024 г. · Novartis Q2 Results | July 18, 2024. Our pipeline projects at a glance. IB&GH: In-market Brands and Global Health. Phase 1/2. Phase 3.

29 окт. 2024 г. · Novartis Q3 Results | October 29, 2024. Our pipeline projects at a glance. IB&GH: In-market Brands and Global Health. Phase 1/2. Phase 3.

Novartis Pipeline. Benefiting from our continued focus on innovation, Novartis has one of the industry's most competitive pipelines. Executive Committee of ...

“Longer term, we've identified more than 30 assets in the pipeline with significant potential to rejuvenate our portfolio and support mid-single ...

8 янв. 2024 г. · Expect to deliver mid-term sales CAGR of +5% and core margin of ~40%+, mainly driven by de-risked in-market brands... Novartis Strategy & Growth ...

18 янв. 2024 г. · Novartis (NVS) is poised to outperform in 2024, backed by a diverse portfolio and a deep pipeline.

18 июл. 2024 г. · We have a clear focus on four core therapeutic areas (cardiovascular-renal-metabolic, immunology, neuroscience and oncology), with multiple ...

23 апр. 2024 г. · Novartis Q1 Results | April 23, 2024. Our pipeline projects at a glance. 29. IB&GH: In-market Brands and Global Health. Phase 1/2. Phase 3.

25 апр. 2023 г. · The Swiss drugmaker has decided to dump or out-license 10% of its R&D projects to narrow its focus on to five core therapeutic areas.